Streetbeat News

TRML

Tourmaline Bio, Inc.

https://www.tourmalinebio.com

Industry

Biotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Tourmaline Bio (NASDAQ:TRML) and maintained a price target of $48.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:31 am

Tourmaline Bio (NASDAQ:TRML) reported a Q2 2024 adjusted EPS of $(0.68), beating the analyst consensus estimate of $(0.71) by 4.23%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:51 pm

Tourmaline Bio, Inc. (NASDAQ: TRML) presented the design of its Phase 2 TRANQUILITY study at the ASPC Congress 2024. The study evaluates the effects of TOUR006 on hs-CRP levels in CKD patients. Topline data is expected in the first half of 2025, potentially advancing TOUR006 to Phase 3 for ASCVD and other cardiovascular diseases.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 8:31 pm

Tourmaline Bio has appointed Ryan Robinson as the new Chief Financial Officer, effective June 25.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:06 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Tourmaline Bio (NASDAQ:TRML) and maintained a $48 price target.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 1:57 pm

Tourmaline Bio reported ending the first quarter with $350.3 million in cash, cash equivalents, and investments, extending its cash runway into 2027.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:19 am

Tourmaline Bio reported its Q1 2024 GAAP earnings per share (EPS) at $(0.55), surpassing the estimated $(0.66).

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:18 am

Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Tourmaline Bio (NASDAQ:TRML) and maintained a $74 price target.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 4:27 pm

FactSet Research Systems Inc. (FDS) shares fell by 5.2% after reporting lower-than-expected Q2 revenue and FY24 guidance. Other stocks showed significant movement, with notable gainers including Yield10 Bioscience, Inc. (YTEN) and losers like Movella Holdings Inc. (MVLA).

Portfolio Pulse from Avi Kapoor

March 21, 2024 | 6:39 pm

Health care stocks showed significant movement in Thursday's intraday session, with notable gainers including Yield10 Bioscience, Monogram Orthopaedics, and X4 Pharmaceuticals, among others. Losers were led by Tourmaline Bio, Apyx Medical, and Ontrak. The movements were largely influenced by recent Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.